-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Surgery Partners, Lowers Price Target to $29

Benzinga·11/13/2025 15:23:30
Listen to the news
UBS analyst A.J. Rice maintains Surgery Partners (NASDAQ:SGRY) with a Buy and lowers the price target from $34 to $29.